An apparatus includes a housing, a fluid reservoir, a flow control mechanism, and an actuator. The housing defines an inner volume and has an inlet port that can be fluidically coupled to a patient and an outlet port. The fluid reservoir is disposed in the inner volume to receive and isolate a first volume of a bodily-fluid. The flow control mechanism is rotatable in the housing from a first configuration, in which a first lumen places the inlet port is in fluid communication with the fluid reservoir, and a second configuration, in which a second lumen places the inlet port in fluid communication with the outlet port. The actuator is configured to create a negative pressure in the fluid reservoir and is configured to rotate the flow control mechanism from the first configuration to the second configuration after the first volume of bodily-fluid is received in the fluid reservoir.

A system includes a first port comprising a first inlet, a first outlet, a first fluid pathway extending from the first inlet to the first outlet, a second inlet, a second outlet, and a second fluid pathway extending from the second inlet to the second outlet. The system further includes one or more CSF catheters having a first lumen, a first distal opening in fluid communication with the first lumen, a second lumen, and a second distal opening in fluid communication with the second lumen. The one or more CSF catheters are, or are configured to be, operatively coupled with the first implantable device such that the first lumen is in fluid communication with the first fluid pathway and the second lumen is in fluid communication with the second fluid pathway. At least the first distal opening is configured to be placed in the CSF-containing space. The system further includes a second port having a third inlet, a third outlet, and a third fluid pathway extending from the third inlet to the third outlet. The system also includes a port catheter configured to operatively couple the third fluid pathway to the second fluid pathway.

An implantable cranial medical device includes a first fluid flow path, a second fluid flow path, and upper flange portion, and a lower portion. The upper flange portion is configured to rest on a skull of a subject about a burr hole. The lower portion is configured to be placed within the burr hole. The first fluid flow path may extend from a first opening in the upper flange portion to a first opening in the lower portion. The second fluid flow path may extend from a second opening in the upper flange portion to a second opening in the lower portion.

Disclosed herein, are compositions, methods, systems, and apparatus for collecting biological material from the nasal cavity of a subject or the olfactory region of a subject's nasal cavity. In some embodiments, the biological material is collected from a targeted sub-region of the nasal cavity, such as a targeted sub-region of the olfactory region, wherein such biological material is specific to the targeted sub-region. In some embodiments, the biological material collected from a targeted sub-region is preserved according to its localization. In some embodiments, the biological material comprises cerebrospinal fluid, one or more microbes of the patient's microbiome, one or more components of the patient's metabolome, one or more pathogens, and/or one or more biomarkers of interest. In some embodiments, a specific formulation is delivered to the region in the nasal cavity for facilitating biological material collection located therein.

A continuous-flow system for the treatment of edema in an injured central nervous system (CNS) tissue, including: a reversibly implantable device having: an inflow pathway, an outflow pathway, and a fluid flow pathway connecting the first outlet of the inflow pathway and the second inlet of the outflow pathway, wherein the fluid flow pathway includes a semi-permeable membrane; a first reservoir; a fluid-driving apparatus; a second reservoir; and a plurality of fluid flow conduits that fluidically connect the first reservoir, the fluid-driving apparatus, the second reservoir, and the reversibly implantable device; wherein the reversibly implantable device is configured to allow direct contact between the semi-permeable membrane and at least a portion of the injured CNS tissue; wherein the system is configured to contain a solution that pass through the fluid flow pathway and induces osmotic flow of water from the injured CNS tissue across the semipermeable membrane and into the solution, thereby decreasing swelling of the tissue. Also disclosed are related methods for removing water from a traumatically injured central nervous system (CNS) tissue in a subject.

Disclosed embodiments include methods and devices for introducing a sheath into a human or animal subject. Some embodiments include a puncture tool that may simultaneously deliver a sheath and a needle to a desired anatomical location. The needle may be removed and the sheath may be used to define a space that may be used to conduct a procedure.

The present disclosure relates to a device for the measurement of fluids and the prevention of infections caused by probes comprising a module of fluid measurement and a probe infection prevention module. The fluid measurement module comprises an electronic module for the measurement of the body fluids; a disposable container for temporary retention of fluid during measurement; a fluid circulation tube arranged between the probe and the disposable container; and a disposable bag for the final disposal of waste fluids. The probe infection prevention module comprises a sheet equipped with adhesive allowing conformation of a flexible structure to the skin or mucosa of the patient. This module incorporates a gel externally that prevents infections, as well as internal antimicrobial components to inhibit passage of microorganisms through the system. The present invention allows non-invasive measurement of fluids utilizing existing probes while contributing to the reduction of infections in patients.

A cannula, in particular for lumbar puncture and lumbar injection, with a proximal end and a distal end, can include a cannula tube with an inner side, and outer side, a cannula canal having a first end region and a second end region. The cannula tube can include at the second end region a tip which forms the distal end of the cannula, and the cannula tube can include an opening of the cannula canal, and a coating is provided about the opening of the cannula canal on the inner side.

Systems, catheters, and methods for accessing and treating along the central nervous system are disclosed including sampling systems. An example sampling system may include a filter cassette designed to filter cerebrospinal fluid. The filter cassette may have an inlet region configured to be coupled to a catheter and configured to receive cerebrospinal fluid, one or more filters, and an outlet region configured to be coupled to an outlet of the catheter and to direct filtered cerebrospinal fluid to the catheter. A sampling port may be in fluid communication with the filter cassette. The sampling port may have a first end region configured to receive cerebrospinal fluid, a stopcock, a syringe port, and a second end region. The stopcock may be configured to shift between a first position where cerebrospinal fluid is directed from the first end region to the second end region and a second position where cerebrospinal fluid is directed from the first end region to the syringe port.

Methods, devices, kits and computer-implemented methods for diagnosing (and optionally treating) tuberculous meningitis (TBM) are provided. In one embodiment, the method comprises testing a cerebrospinal fluid (CSF) sample from a subject suspected of having TBM for the presence of MPO and at least two other biomarkers, at least one of the other biomarkers being selected from the group consisting of IFN-γ, sICAM-1, VEGF-A and CXCL8. For example, the method can comprise testing the sample for MPO, IFN-γ and VEGF-A or for MPO, IFN-γ, sICAM-1 and CXCL8. In another embodiment, the method comprises testing a blood sample from a subject suspected of having TBM for the presence of at least one biomarker selected from the group consisting of adipsin (complement factor D), Ab42 and IL-10, and at least two other biomarkers. In one example, the method comprises testing the sample for the presence of adipsin (complement factor D), Ab42 and EL-10.